Abstract #1121
Monitoring quantitative tumor blood volume in mouse brain under Bevacizumab by the RSST1-MRI method.
Michel Sarraf 1,2 , Flavien Caraguel 1 , Franois Berger 1 , Boudewijn Van Der Sanden 1 , and Hana Lahrech 1
1
CEA-CLINATEC, Grenoble, Isre, Rhne-Alpes,
France,
2
Saint
Joseph University, Beyrouth, Lebanon
Blood volume fraction (BVf) and vessel permeability have
been shown to indicate anti-angiogenic therapy response
at an early stage (before changes in tumor size appear).
This study demonstrates the sensitivity of the RSST1-MRI
method to quantify BVf, to detect the vasculature
changes in U87 human glioblastoma cell (in mouse brain)
at an early stage, after treatment with Bevacizumab,
which is injected intravenously at a dose of 10 mg/kg
(Student t-test: Pvalue <0.05). RSST1 is suitable to
assess the effect of new anti-angiogenic therapies, and
help physicians to take early decisions to stop,
continue or change therapy strategies during treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
